Compare Herbalife Nutrition Ltd (HLF) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while Recursion Pharmaceuticals Inc trades at $4.32 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 1,589,457). Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| HLF | RXRX | |
|---|---|---|
Market Cap | $1.34B | $2.14B |
Volume | 1,589,457 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $6.79 |
52-Week Low | $7.75 | $2.84 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $3.18B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $12.86, up 1.62% on the day, with a bullish technical signal and a consensus analyst price target of $19.00 implying significant upside. The company reported Q2 2026 EPS of $0.51, missing expectations, but reaffirmed full-year 2026 guidance. Financials show a net income margin of 3.16% for 2025, with a low P/E of 8.22 and P/S of 0.26, suggesting potential undervaluation. Recent news includes a $250 million share repurchase authorization and a planned CEO transition effective October 31, 2026.
The outlook for HLF is cautiously optimistic, with valuation metrics and analyst sentiment supporting a bullish case, but risks include recent earnings misses, high debt levels, and ongoing leadership changes. The stock presents a value opportunity if the company can execute on its growth and margin expansion plans while managing its leverage.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
